@FierceBiotech: Why would Pfizer want to buy AstraZeneca? It's not R&D. More | Follow @FierceBiotech
@JohnCFierce: And that PhII failure wasn't a failure. No sir. Not at all. It was a success. Because Concert says so. All perfectly clear now. | Follow @JohnCFierce
@DamianFierce: BMY's taking the rolling FDA submission approach with much-watched cancer drug nivolumab. Story | Follow @DamianFierce
@EmilyMFierce: Another chink in HIV's armor may point the way to a vaccine. More from FierceBiotech Research | Follow @EmilyMFierce
> Shares of Chapel Hill, NC-based Pozen ($POZN) were dented after the FDA rejected its application for PA8140/PA32540 (aspirin and omeprazole), a combo pain reliever designed for people at risk of developing a gastric ulcer. The biotech says the CRL was spurred by deficiencies found during an "inspection of the manufacturing facility of an active ingredient supplier that concluded this week." Release
> GlobeImmune has laid out terms for its upcoming IPO, looking to sell 2.2 million shares at $15 to $17 each. Story
> Lupin and Japan's Yoshindo have formed a joint venture to develop and market new biosimilars. Story
@FierceMedDev: Luminex reports higher Q1 revenues despite earlier warnings. Article | Follow @FierceMedDev
@VarunSaxena2: Alere to sell stake in BBI Diagnostics Group subsidiary in bid to keep activist investor Coppersmith Capital Management at bay. | Follow @VarunSaxena2
@EmilyWFierce: It's a full menagerie in this week's issue of FierceBiotechResearch: Here's the issue | Follow @EmilyWFierce
@MichaelGFierce: ICYMI from FierceDrugDelivery: Imaging technique maps transdermal drug migration. More | Follow @MichaelGFierce
> Diagnostics firm Indi snags $47.3M for lung tests. More
> GE launches Alzheimer's imaging agent in a cloudy market. Report
> Boston Scientific swings to a profit amid its turnaround plan. Article
Pharma News
@FiercePharma: Looking for more megadeal excitement? Don't look at Sanofi, CEO says. Story | Follow @FiercePharma
@TracyStaton: Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons. A biggie = "synergies," i.e. cost cuts. More | Follow @TracyStaton
@EricPFierce: The FDA is letting Baxter import saline from a plant in Spain to help ease the shortage in the US. More from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Allergan to propose to Shire again, but does Irish beauty want to get engaged? Article | Follow @CarlyHFierce
> The skinny on earnings: Cost cuts boost Merck, Bristol-Myers, Forest as FX hits Sanofi. Piece
> Pfizer's post-megamerger cost-cutting record? 51,500 jobs in 7 years. Story
> Reckitt is indeed after Merck's consumer unit, and it's ready for a close race. Item
Biotech Research News
> Another chink in HIV's armor may point the way to a vaccine. Article
> Protein found in naked mole rats could shed light on Alzheimer's, Parkinson's development. More
> Deadly MERS outbreak blamed on camels. Report
> Rutgers wins $26M NIH grant to help fill lackluster antibiotics pipeline. Report
> Preclinical study advances H. pylori vaccine for stomach cancer. Item
> Single molecule that targets both amyloid and tau could treat Alzheimer's. Story
Pharma Manufacturing News
> Sanofi supply-chain issues again put hurt on its earnings. News
> Baxter adds saline production from Spain to U.S. supply. Story
> FDA loses another top dog in quality to Mylan. Item
> Takeda snags another big subsidy for influenza vaccine plant in Japan. More
> Indian ban on Wockhardt plant lifted by top Indian regulator. Article